期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗鲍曼不动杆菌药物研究进展

Research Advances in Antibacterial Agents Resistance to Acinetobacter baumannii
下载PDF
导出
摘要 鲍曼不动杆菌已经成为院内感染的主要病原体,并且随着多重耐药鲍曼不动杆菌(MDRAB)的增加,对它的治疗已经受到重视。本文着重介绍了针对多重耐药鲍曼不动杆菌的抗生素,药物联用仍是有效方法。新型肽类抗生素如人β-防卫素2、(LLKK)2C和[E4K]alyteserin-1c等具有抗菌活性高、副作用小等优点,具有很好的应用前景。 Acinetobacter baumannii had emerged as a major pathogen causing hospital infections. With the increase of multidrug-resistant Acinetobacter baumannii （MDRAB）, there is a clear need to seek therapeutic approaches. Antibacterial agents for MDRAB infections were mainly introduced in this article. Combination of antibiotics was still the effective method. New peptide antibiotics such as Human β-defensin 2, （LLKK）2C and [E4K] alyteserin-1c could hopefully be ideal antibacterial agents with advantages of potent antibacterial activity and little side effects.
作者 刘坤锋 吴洁 顾觉奋
机构地区 中国药科大学生命科学与技术学院
出处 《国外医药（抗生素分册）》 CAS 2013年第5期193-196,共4页 World Notes on Antibiotics
关键词 MDRAB 耐药 联合用药 抗菌肽 MDRAB resistance combination ofdrugs antimicrobial peptides
分类号 R378 [医药卫生—病原生物学]
  • 相关文献

参考文献25

  • 1汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,孙宏莉,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2007年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2008,8(5):325-333. 被引量：305
  • 2胡付品,朱德妹,汪复,蒋晓飞,杨青,徐英春,张小江,孙自镛,陈中举,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,单斌,杜艳,徐元宏,沈继录,张泓,孔菁,卓超,苏丹虹,张朝霞,季萍,胡云建,艾效曼,黄文祥,贾蓓,魏莲花,吴玲.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. 被引量：526
  • 3Chen Y, Zhou Z, Jing Y, et al. Emergence of NDM- 1-producing Acinetobacter baumannii in China[J]. J antimicrob chemoth, 2011, 66(6): 1255.
  • 4Park S, Lee KM, Yoo YS, et al. Alterations of gyrA, gyrB, and parC and activity of effiux pump in fluoroquinolone- resistant Acinetobacter baumannii[J]. Osong Public Health and Research Perspectives, 2011, 2(3):164.
  • 5washkiw JA, Seper A,Weber BS, et al.Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation[J]. PloS Pathogens, 2012, 8(6):e1002758.
  • 6Kuo HK,Chang KC, Kuo JW, et al. Imipenem: a potent inducer of multidrug resistance in Acinetobacter baumannii[J]. Intern J Antimicrob Agents, 2012, 39(1):33.
  • 7Peck KR, Kim M J, Choi JY, et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem- resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates[J]. J Med Microbiol, 2012, 61(Pt 3):353.
  • 8Pichardo C, Pachon ME, Docobo F, et al. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia[J]. Europ J Clin Microbiol Infec Diseases, 2010, 29(5):527.
  • 9Tang HJ, Chuang YC, Ko WC, et al.Comparative evaluation of intratracheal colistimethate sodium, imipenem,and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia[J]. Intern J Infec Dis, 2012,16(1)'34.
  • 10Ozbek B, Otuk G. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units[J]. Intern J Antimicrob Agents, 2010, 36(2): 191.

二级参考文献17

  • 1Clinical and Laboratory Standards Institute(CLSI). Performance Standards for Antimicrobial susceptibility testing[S]. 2007.
  • 2Rodriguez-Bano J, Paterson DL. A change in the epidemicology of infections due to exterded spectrum β-lactamase producing organisms[J]. Clin Infect Dis, 2006,42(7) :935-937.
  • 3Paterson DL. The epidemiological profile of infections with multidrug resistant Preudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis ,2006, 43(suppl 2):S43-S48.
  • 4Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa[J].Clin Infect Dis, 2006, 43(suppl 2):S49-S56.
  • 5Zavascki AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review[J].J Anitmicrob Chemother, 2007, 60(6) : 1206-1215.
  • 6Li J, Nation RL, Turnidge JD, et al. Colistin:the re-emerging antibiotic for multidrug-resistant Gram-regative bacterial infections[J]. Lancet Infect Dis, 2006, 6(9) : 589-601.
  • 7Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis, 2006, 43 ( suppl 2) : S95- S99.
  • 8Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
  • 9Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
  • 10Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.

共引文献804

国外医药（抗生素分册）
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部